

6. Jiráček D, Kriz J, Herynek V, et al. MRI of transplanted pancreatic islets. *Magn Reson Med*. 2004;52:1228–1233.
7. Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A. In vivo imaging of islet transplantation. *Nat Med*. 2006;12:144–148.
8. Brom M, Andralojc K, Oyen WJ, Boerman OC, Gotthardt M. Development of radiotracers for the determination of the beta-cell mass in vivo. *Curr Pharm Des*. 2010;16:1561–1567.
9. Wu Z, Liu S, Hassink M, et al. Development and evaluation of ¹⁸F-TTCO-Cys40-exendin-4: a PET probe for imaging transplanted islets. *J Nucl Med*. 2013;54:244–251.
10. Christoffersson G, Henriksnas J, Johansson L, et al. Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. *Diabetes*. 2010;59:2569–2578.
11. Rafael E, Tibell A, Ryden M, et al. Intramuscular autotransplantation of pancreatic islets in a 7-year-old child: a 2-year follow-up. *Am J Transplant*. 2008;8:458–462.
12. Stegall MD. Monitoring human islet allografts using a forearm biopsy site. *Ann Transplant*. 1997;2:8–11.
13. Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. *N Engl J Med*. 2010;363:1289–1290.
14. Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC. Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas. *Contrast Media Mol Imaging*. 2012;7:160–166.
15. Brom M, Woliner-van der Weg W, Joosten L, et al. Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin. *Diabetologia*. 2014;57:950–959.
16. Berkova Z, Kriz J, Girman P, et al. Vitality of pancreatic islets labeled for magnetic resonance imaging with iron particles. *Transplant Proc*. 2005;37:3496–3498.
17. Tai JH, Foster P, Rosales A, et al. Imaging islets labeled with magnetic nanoparticles at 1.5 Tesla. *Diabetes*. 2006;55:2931–2938.
18. Koblas T, Girman P, Berkova Z, et al. Magnetic resonance imaging of intra-hepatically transplanted islets using paramagnetic beads. *Transplant Proc*. 2005;37:3493–3495.
19. Wu H, Liang S, Liu S, Pan Y, Cheng D, Zhang Y. ¹⁸F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals. *Nucl Med Commun*. 2013;34:701–708.
20. Wu Z, Todorov I, Li L, et al. In vivo imaging of transplanted islets with ⁶⁴Cu-DO3A-VS-Cys40-exendin-4 by targeting GLP-1 receptor. *Bioconjug Chem*. 2011;22:1587–1594.

Erratum

In Table 2 of the article “Biodistribution and Radiation Dosimetry of the Synthetic Nonmetabolized Amino Acid Analogue *Anti*-¹⁸F-FACBC in Humans,” by Nye et al. (*J Nucl Med*. 2007;48:1017–1020), certain units of measurement in the column headers are incorrect. The corrected table appears in full below. The authors regret the error.

TABLE 2
Mean Radiation-Absorbed Dose Estimates for *Anti*-¹⁸F-FACBC Obtained from MIRDOSE Adult Model

Organ	μGy/MBq	mrad/mCi	μSv/MBq	mrem/mCi
Liver	52.2	193.0		
Pancreas	31.5	116.0		
Heart wall	22.3	82.3		
Kidneys	22.1	81.8		
Spleen	20.2	74.9		
Gallbladder	17.8	66.0		
Red marrow	15.4	56.8		
Adrenals	14.8	54.8		
Muscle	14.7	54.2		
Stomach	13.0	48.1		
Bone surfaces	12.9	47.7		
Urinary bladder wall	11.9	44.2		
Upper large intestine	11.8	43.5		
Lungs	11.7	43.4		
Ovaries	11.6	43.0		
Uterus	11.5	42.5		
Small intestine	11.4	42.2		
Lower large intestine	10.9	40.3		
Thymus	10.0	37.0		
Thyroid	9.4	34.9		
Testes	8.6	31.9		
Brain	8.2	30.4		
Skin	7.0	25.7		
Breasts	4.4	16.1		
Total body	12.8	47.4		
Effective dose equivalent			16.4	60.6
Effective dose			14.1	52.2

Organs are listed in descending order.